The Clinical Trial Vanguard: Pheast Therapeutics Advances New Cancer Drug to Phase 1b Trial

The Clinical Trial Vanguard reports that Pheast Therapeutics has advanced its lead anti CD24 macrophage checkpoint inhibitor, PHST001, into the Phase 1b combination portion of its ongoing clinical study, with the first patient dosed. The article highlights Pheast’s strategy to evaluate PHST001 alongside standard chemotherapy regimens in ovarian, endometrial, and cholangiocarcinoma, reflecting encouraging early safety and pharmacodynamic signals from Phase 1a monotherapy and continued progress toward clinical proof of concept.

Read the full article here.